4-苯胺-1-甲基哌啶 | 22261-94-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-苯胺-1-甲基哌啶
• 中文别名: 1-甲基-4-(N-苯基)氨基哌啶；4-苯胺-1-甲基哌啶,98
• 英文名称: N-(1-methyl-4-piperidinyl)aniline
• 英文别名: 1-methyl-N-phenylpiperidin-4-amine；N-(1-methyl-4-piperidinyl)-N-phenylamine
• CAS: 22261-94-5
• 化学式: C₁₂H₁₈N₂
• 分子量: 190.288
• InChiKey: GXJSWUKLJQHQFZ-UHFFFAOYSA-N

物化性质

• 熔点：
  82-86°C
• 沸点：
  110-120 °C(Press: 0.1 Torr)
• 密度：
  1.042±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  <p><b></b></p>

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 储存条件：
  <p><br></p>

制备方法与用途

合成制备方法
用途

反应信息

• 作为反应物：
  描述：

  4-苯胺-1-甲基哌啶 在 sodium hydroxide 、 sodium tetrahydroborate 、 三氯化硼 作用下， 以 1,4-二氧六环 、 乙醇 、 乙二醇 、 1,2-二氯乙烷 为溶剂， 反应 5.0h， 生成 1-哌啶-4-基-1H-吲哚
  参考文献：
  名称：

  Sasakura, Kazuyuki; Adachi, Makoto; Sugasawa, Tsutomu, Synthetic Communications, 1988, vol. 18, # 3, p. 265 - 274

  摘要：

  DOI：
• 作为产物：
  描述：

  1-甲基-N-苯基哌啶-4-亚胺 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 以60.7%的产率得到4-苯胺-1-甲基哌啶
  参考文献：
  名称：

  Synthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain

  摘要：

  Acids 9a-f as possible bivalent ligands designed as a structural combination of opioid mu-agonist (Fentanyl) and NSAID ( Indomethacin) activities and produced compounds which were tested as analgesics. The obtained series of compounds exhibits low affinity and activity both at opioid receptors and as cyclooxygenase ( COX) inhibitors. One explanation of the weak opioid activity could be stereochemical peculiarities of these bivalent compounds which differ significantly from the fentanyl skeleton. The absence of significant COX inhibitory properties could be explained by the required substitution of an acyl fragment in the indomethacin structure for 4-piperidyl. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2009.05.065

文献信息

• Reductive Alkylation of Aromatic Amines with Enol Ethers
  作者：T. Jagadeeswar Reddy、Michael Leclair、Melanie Proulx

  DOI：10.1055/s-2005-863704

  日期：——

  Reductive alkylation of aromatic amines with 2-meth­oxypropene using 1.0 equivalent of HOAc and NaBH(OAc)3 in 1,2-dichloroethane (DCE) at room temperature furnished N-isopropyl amines in 50-98% yields. This method was successfully extended to trimethylsilyl enol ethers. The mild reaction conditions provide a new alternative procedure for the reductive amination of electron deficient aromatic amines

  在室温下，在 1,2-二氯乙烷 (DCE) 中使用 1.0 当量的 HOAc 和 NaBH(OAc) 3 对芳香胺与 2-甲氧基丙烯进行还原烷基化，以 50-98% 的产率提供 N-异丙基胺。该方法成功地扩展到三甲基甲硅烷基烯醇醚。温和的反应条件为缺电​​子芳香胺的还原胺化提供了一种新的替代方法。
• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018071454A1

  公开（公告）日：2018-04-19

  Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供了Formula I的化合物：(I)或其药用可接受的盐或溶剂，其中A、B、X1、X2、X3、X4、环D、E、Ra、Rb、n和m的含义如规范中所述，它们是RET激酶的抑制剂，并且在治疗和预防可以用RET激酶抑制剂治疗的疾病中非常有用，包括与RET相关的疾病和紊乱。
• FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
  申请人：Sarepta Therapeutics, Inc.

  公开号：US20140330006A1

  公开（公告）日：2014-11-06

  Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

  提供了包含修改的亚单位间连接和/或修改的3'和/或5'-末端基团的功能修饰寡核苷酸类似物。所公开的化合物对于治疗需要抑制蛋白质表达或纠正异常mRNA剪接产物以产生有益治疗效果的疾病是有用的。
• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINES COMME INHIBITEURS DE LA KINASE RET
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2017011776A1

  公开（公告）日：2017-01-19

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供了一般式I的化合物及其立体异构体和药用可接受的盐或溶剂，其中A、B、D、E、X1、X2、X3和X4的含义如规范中所述，这些化合物是RET激酶的抑制剂，可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括由RET激酶介导的疾病或紊乱。
• SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR
  申请人：Bonaventure Pascal

  公开号：US20070100141A1

  公开（公告）日：2007-05-03

  The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; sleep/wake disorders; cardiovascular disease; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.

  这项发明提供了新型的非肽类NPY Y2受体抑制剂，可用于治疗或预防：抗焦虑障碍或抑郁症；受损的哺乳动物神经组织；通过给予神经营养因子进行治疗的疾病；神经系统疾病；骨质流失；与物质相关的障碍；睡眠/清醒障碍；心血管疾病；肥胖症；或与肥胖相关的疾病。该发明的化合物还可用于调节内分泌功能，特别是垂体和下丘脑腺控制的内分泌功能，并因此可用于治疗或预防排卵障碍和不孕症。